zk1313166.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 22, 2013 (May 21, 2013)

PLURISTEM THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Its Charter)

Nevada
(State or Other Jurisdiction of Incorporation)

001-31392
  
98-0351734
(Commission File Number)
  
(IRS Employer Identification No.)

MATAM Advanced Technology Park
Building No. 5
Haifa, Israel
  
31905
(Address of Principal Executive Offices)
  
(Zip Code)

011 972 74 710 7171
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 5.07.  Submission of Matters to a Vote of Security Holders.

Pluristem Therapeutics Inc. (the “Company”), held its annual meeting of stockholders on May 21, 2013. The results of the stockholder voting at the annual meeting are set forth below.

Stockholders voted on the matters set forth below:

Proposal No. 1 — Election of Directors

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

Director Name
  
For
    
Against
    
Abstain
    
Broker Non-Votes
  
                         
Zami Aberman
    
10,524,983
      
1,693,895
      
32,411
      
16,259,162
  
                                 
Israel Ben-Yoram
    
12,072,682
      
75,845
      
102,762
      
16,259,162
  
                                 
Isaac Braun
    
12,075,388
      
74,420
      
101,481
      
16,259,162
  
                                 
Mark Germain
    
12,057,290
      
92,518
      
101,481
      
16,259,162
  
                                 
Moria Kwiat
    
12,017,624
      
129,784
      
103,881
      
16,259,162
  
                                 
Hava Meretzki
    
12,004,820
      
170,707
      
75,762
      
16,259,162
  
                                 
Nachum Rosman
    
12,062,603
      
87,245
      
101,441
      
16,259,162
  
                                 
Doron Shorrer
    
12,041,363
      
118,197
      
91,729
      
16,259,162
  

Proposal No. 2 — Advisory Vote on the Compensation of our Named Executive Officers

For
    
Against
    
Abstain
    
Broker Non-Votes
  
                     
 
10,264,977
      
1,834,739
      
151,573
      
16,259,162
  

Proposal No. 3 — Advisory Vote on the Frequency of the Advisory Vote on Compensation of our Named Executive Officers

1 Year
    
2 Years
    
3 Years
    
Abstain
    
Broker Non-Votes
  
                           
  3,296,595      
7,492,304
      
1,109,624
      
352,766
      
16,259,162
  

Proposal No. 4 — Ratification of the Selection of Kost Forer Gabbay & Kasierer, a Member of Ernst & Young Global, as Independent Registered Public Accounting Firm of the Company for the Fiscal Year Ending June 30, 2013

For
    
Against
    
Abstain
    
Broker
Non-Votes
  
                     
 
27,754,826
      
224,670
      
530,955
    
-
  
 
The results reported above are final voting results.
 
In accordance with the stockholder voting results, in which every “Two Years” received the highest number of votes cast on the frequency proposal, and our Board of Directors’ recommendation in the proxy statement for the 2013 annual meeting of stockholders, our Board of Directors has determined that future stockholder advisory (non-binding) votes on the compensation of our named executive officers will occur every two years. Accordingly, the next stockholder advisory (non-binding) vote on executive compensation will be held at our 2015 annual meeting of stockholders.

 
 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PLURISTEM THERAPEUTICS INC.
  
     
Date: May 22, 2013
By:
/s/ Yaky Yanay
  
 
Name:
 Yaky Yanay
  
 
Title:
Executive Vice President,
Chief Financial Officer and Secretary